Literature DB >> 1549057

Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death.

M Weinberger1, I Elattar, D Marshall, S M Steinberg, R L Redner, N S Young, P A Pizzo.   

Abstract

Patterns of infection were studied in 150 patients with aplastic anemia who were admitted to the Clinical Hematology Branch, National Institutes of Health, between January 1978 and December 1989 for immunosuppressive therapy. Sixty percent of the patients were males, 71% were white, their mean age was 33.6 years (median, 27.5; range, 1-75), and 83% had severe aplastic anemia. One hundred three patients developed 1 or more febrile episodes during the study period. The risk factors for developing a febrile episode included a low Absolute Neutrophil Count (ANC) and Absolute Monocyte Count (AMC) at admission and the presence of an indwelling central venous catheter (Hickman-Broviack or Port-A-Cath). A total of 289 febrile events were studied, including unexplained fever (FUO) in 89 (31%), microbiologically documented infection (MBDI) in 137 (47%), and clinically documented infection (CDI) in 63 patients (22%). Compared to documented infections (MBDI) or CDI), FUO events were associated with a higher frequency of rigors, signs and symptoms of serum sickness, and treatment regimens known to cause fevers. None of the FUO events had a fatal outcome, even if the antibiotic therapy was discontinued before day 7. Among CDI events, bacteria were the most commonly defined etiologic agent (67%), followed by fungi (23%), viruses (7%), and parasites (3%). The patterns of bacterial infections in patients with aplastic anemia were similar to those observed in patients with cancer-related neutropenia. Twenty-one patients (15%) developed invasive fungal infections (aspergillus, 11; candida, 7; and both, 3), which were fatal in 19 (90%). Fungal infections accounted for 30% of the secondary infectious events and for 55% of fatal infectious events. The only identifiable risk factors for developing a fungal infection were the degree of neutropenia and monocytopenia at initial admission or final evaluation. Invasive pulmonary aspergillosis developed despite empirical amphotericin B therapy and was associated with a high incidence of fatal pulmonary hemorrhage (10 of 13 patients [77%]). Infection was responsible for 36 (62%) of the deaths observed during the study period and hemorrhage alone for 4 (7%). However, 20 of the patients who died of infection had concomitant hemorrhage. No significant drop in ANC, AMC, or platelet count could be demonstrated during a fatal infectious event as compared to a nonfatal infectious event. Invasive fungal infections, predominantly with aspergillus and candida, emerged in our study as the major causes of mortality in patients with aplastic anemia. Without bone marrow recovery the prognosis associated with invasive mycoses was grave.

Entities:  

Mesh:

Year:  1992        PMID: 1549057     DOI: 10.1097/00005792-199201000-00003

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  23 in total

1.  Pancytopenia associated with bone marrow aplasia in a Holstein heifer.

Authors:  V J Ammann; G Fecteau; P Hélie; M Desnoyer; P Hébert; M Babkine
Journal:  Can Vet J       Date:  1996-08       Impact factor: 1.008

2.  Granulocyte transfusions in severe aplastic anemia: an eleven-year experience.

Authors:  Karen Quillen; Edward Wong; Phillip Scheinberg; Neal S Young; Thomas J Walsh; Colin O Wu; Susan F Leitman
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

Review 3.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

4.  Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.

Authors:  Phillip Scheinberg; Danielle Townsley; Bogdan Dumitriu; Priscila Scheinberg; Barbara Weinstein; Maithili Daphtary; Olga Rios; Colin O Wu; Neal S Young
Journal:  Blood       Date:  2014-09-03       Impact factor: 22.113

5.  Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.

Authors:  Jessica M Valdez; Phillip Scheinberg; Olga Nunez; Colin O Wu; Neal S Young; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2011-03-15       Impact factor: 9.079

Review 6.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

7.  Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

8.  Specific interaction of Aspergillus fumigatus with fibrinogen and its role in cell adhesion.

Authors:  P Coulot; J P Bouchara; G Renier; V Annaix; C Planchenault; G Tronchin; D Chabasse
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

9.  Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.

Authors:  E Roilides; K Uhlig; D Venzon; P A Pizzo; T J Walsh
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.